A Phase I Trial Assessing the Feasibility of Romidepsin Combined With Brentuximab Vedotin for Patients With Requiring Systemic Therapy for Cutaneous T-cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Romidepsin (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Adverse reactions
- 30 May 2017 Status changed from not yet recruiting to recruiting.
- 25 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
- 25 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.